PRKDC and urinary bladder cancer: This study aims at assessing the impact of a potent and selective DNA-PK inhibitor (DNA-PKi: AZD7648) and an ATR inhibitor (ATRi: Ceralasertib) to foster radiosensitization of bladder cancer cells in vitro.